MyMedR

Displaying all 4 publications

Abstract:

Sort:

Overcoming Limitations of LoRa Physical Layer in Image Transmission

Jebril AH, Sali A, Ismail A, Rasid MFA

Sensors (Basel), 2018 Sep 27;18(10).
PMID: 30262793 DOI: 10.3390/s18103257

As a possible implementation of a low-power wide-area network (LPWAN), Long Range (LoRa) technology is considered to be the future wireless communication standard for the Internet of Things (IoT) as it offers competitive features, such as a long communication range, low cost, and reduced power consumption, which make it an optimum alternative to the current wireless sensor networks and conventional cellular technologies. However, the limited bandwidth available for physical layer modulation in LoRa makes it unsuitable for high bit rate data transfer from devices like image sensors. In this paper, we propose a new method for mangrove forest monitoring in Malaysia, wherein we transfer image sensor data over the LoRa physical layer (PHY) in a node-to-node network model. In implementing this method, we produce a novel scheme for overcoming the bandwidth limitation of LoRa. With this scheme the images, which requires high data rate to transfer, collected by the sensor are encrypted as hexadecimal data and then split into packets for transfer via the LoRa physical layer (PHY). To assess the quality of images transferred using this scheme, we measured the packet loss rate, peak signal-to-noise ratio (PSNR), and structural similarity (SSIM) index of each image. These measurements verify the proposed scheme for image transmission, and support the industrial and academic trend which promotes LoRa as the future solution for IoT infrastructure.
The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge

Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O

J Clin Pharm Ther, 2013 Apr;38(2):97-100.
PMID: 23441979 DOI: 10.1111/jcpt.12027

Pharmacists have the knowledge regarding optimal use of medications and the ability to influence physician prescribing. Successful interventions by a pharmacist to implement cardioprotective medications to a coronary artery disease patient's regimen would not only improve the patient's quality of care but may also increase his or her likelihood of survival. Therefore, the aim of this study was to (i) evaluate the effectiveness of pharmacist initiated interventions in increasing the prescription rates of acute coronary syndrome (ACS) secondary prevention pharmacotherapy at discharge, and to (ii) evaluate the acceptance rate of these interventions by prescribers.
Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice

Kassab YW, Hassan Y, Aziz NA, Akram H, Ismail O

J Eval Clin Pract, 2013 Aug;19(4):658-63.
PMID: 22845427 DOI: 10.1111/j.1365-2753.2012.01894.x

RATIONALE: Despite the availability of various prevention guidelines on acute coronary syndrome (ACS), secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal.
AIMS AND OBJECTIVES: To review and document the utilization of pharmacotherapy for the secondary prevention of ACS in patients discharged from a Malaysian hospital.
METHODS: A retrospective cross-sectional study was conducted at a tertiary hospital in Penang, Malaysia. Patients with a primary diagnosis of ACS were identified from medical records over a 4-month period. A range of clinical data was extracted from medical records, including medical history, clinical presentation and pharmacotherapy both on admission and at discharge. This audit focused on the use of four guideline-recommended therapies: aspirin ± clopidogrel, beta-blockers, statins and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blockers (ARBs).
RESULTS: Data pertaining to a total of 380 ACS patients was extracted and reviewed, the mean age of the study population was 57.49 years and 73.9% of population was males. Patients with unstable angina accounted for 56.6% of the admissions whereas 23.4% and 20% of the patients were admitted for ST-elevation myocardial infarction and non-ST-segment elevation infarct respectively. 95.7% of the patients received antiplatelets comprising of at least aspirin, and 82% received aspirin plus clopidogrel. Furthermore, 80.3% of the patients received a beta-blocker at discharge, 95% a statin and 69.7% received either an ACEI or ARB. Compared with patients who presented with myocardial infarction (with or without ST-segment elevation), those presenting with unstable angina were less likely to receive the combination of aspirin plus clopidogrel or an ACEI/ARB at discharge. Patients over 65 years of age were also less likely to receive a beta-blocker at discharge, compared with younger patients.
CONCLUSIONS: There is a good adherence to evidence-based guidelines for the secondary prevention of ACS in this local setting. However, there is some potential underutilization in the older population and patients presenting with unstable angina.
KEYWORDS: acute coronary syndromes; evidence-based pharmacotherapy; secondary prevention; utilization
In vitro comparative study of white and dark polycaprolactone trifumarate in situ cross-linkable scaffolds seeded with rat bone marrow stromal cells

Muhammad KB, Abas WA, Kim KH, Pingguan-Murphy B, Zain NM, Akram H

Clinics (Sao Paulo), 2012;67(6):629-38.
PMID: 22760903

OBJECTIVE: Dark poly(caprolactone) trifumarate is a successful candidate for use as a bone tissue engineering scaffold. Recently, a white polymeric scaffold was developed that shows a shorter synthesis time and is more convenient for tissue-staining work. This is an in vitro comparative study of both the white and dark scaffolds.
METHODS: Both white and dark poly(caprolactone) trifumarate macromers were characterized via Fourier transform infrared spectroscopy before being chemically cross-linked and molded into disc-shaped scaffolds. Biodegradability was assessed by percentage weight loss on days 7, 14, 28, 42 and 56 (n = 5) after immersion in 10% serum-supplemented medium or distilled water. Static cell seeding was employed in which isolated and characterized rat bone marrow stromal cells were seeded directly onto the scaffold surface. Seeded scaffolds were subjected to a series of biochemical assays and scanning electron microscopy at specified time intervals for up to 28 days of incubation.
RESULTS: The degradation of the white scaffold was significantly lower compared with the dark scaffold but was within the acceptable time range for bone-healing processes. The deoxyribonucleic acid and collagen contents increased up to day 28 with no significant difference between the two scaffolds, but the glycosaminoglycan content was slightly higher in the white scaffold throughout 14 days of incubation. Scanning electron microscopy at day 1 [corrected] revealed cellular growth and attachment.
CONCLUSIONS: There was no cell growth advantage between the two forms, but the white scaffold had a slower biodegradability rate, suggesting that the newly synthesized poly(caprolactone) trifumarate is more suitable for use as a bone tissue engineering scaffold.